NCT05036668View on ClinicalTrials.gov

Study of Efficacy and Safety of ABO809 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

December 27, 2022

Conditions
Cryptosporidium Infection, Cryptosporidiosis
Interventions
BIOLOGICAL

Cryptosporidium parvum oocysts (ABO809)

ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1

Trial Locations (1)

21201

Novartis Investigative Site, Baltimore

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY